Logo image of TXG

10X GENOMICS INC-CLASS A (TXG) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TXG - US88025U1097 - Common Stock

15.76 USD
+0.3 (+1.94%)
Last: 12/15/2025, 8:00:02 PM
15.76 USD
0 (0%)
After Hours: 12/15/2025, 8:00:02 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to TXG. TXG was compared to 57 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for TXG as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, TXG is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TXG has reported negative net income.
In the past year TXG had a positive cash flow from operations.
TXG had negative earnings in each of the past 5 years.
In the past 5 years TXG reported 4 times negative operating cash flow.
TXG Yearly Net Income VS EBIT VS OCF VS FCFTXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M -500M

1.2 Ratios

The Return On Assets of TXG (-7.43%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -9.72%, TXG is in line with its industry, outperforming 54.39% of the companies in the same industry.
Industry RankSector Rank
ROA -7.43%
ROE -9.72%
ROIC N/A
ROA(3y)-20.81%
ROA(5y)-25.31%
ROE(3y)-26.91%
ROE(5y)-32.26%
ROIC(3y)N/A
ROIC(5y)N/A
TXG Yearly ROA, ROE, ROICTXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

TXG has a Gross Margin of 68.90%. This is amongst the best in the industry. TXG outperforms 91.23% of its industry peers.
TXG's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for TXG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.17%
GM growth 5Y-2.02%
TXG Yearly Profit, Operating, Gross MarginsTXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
TXG has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TXG has more shares outstanding
TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TXG Yearly Shares OutstandingTXG Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TXG Yearly Total Debt VS Total AssetsTXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

TXG has an Altman-Z score of 3.60. This indicates that TXG is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.60, TXG is in the better half of the industry, outperforming 71.93% of the companies in the same industry.
TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.6
ROIC/WACCN/A
WACC10.46%
TXG Yearly LT Debt VS Equity VS FCFTXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 4.48 indicates that TXG has no problem at all paying its short term obligations.
TXG's Current ratio of 4.48 is fine compared to the rest of the industry. TXG outperforms 73.68% of its industry peers.
A Quick Ratio of 4.06 indicates that TXG has no problem at all paying its short term obligations.
TXG's Quick ratio of 4.06 is fine compared to the rest of the industry. TXG outperforms 73.68% of its industry peers.
Industry RankSector Rank
Current Ratio 4.48
Quick Ratio 4.06
TXG Yearly Current Assets VS Current LiabilitesTXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 54.25% over the past year.
TXG shows a small growth in Revenue. In the last year, the Revenue has grown by 1.92%.
The Revenue has been growing by 19.96% on average over the past years. This is quite good.
EPS 1Y (TTM)54.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
Revenue 1Y (TTM)1.92%
Revenue growth 3Y7.58%
Revenue growth 5Y19.96%
Sales Q2Q%-1.75%

3.2 Future

The Earnings Per Share is expected to grow by 16.65% on average over the next years. This is quite good.
The Revenue is expected to grow by 4.05% on average over the next years.
EPS Next Y67.35%
EPS Next 2Y16.87%
EPS Next 3Y15.55%
EPS Next 5Y16.65%
Revenue Next Year4.41%
Revenue Next 2Y0.38%
Revenue Next 3Y2.98%
Revenue Next 5Y4.05%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TXG Yearly Revenue VS EstimatesTXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TXG Yearly EPS VS EstimatesTXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

TXG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TXG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TXG Price Earnings VS Forward Price EarningsTXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, TXG is valued cheaper than 80.70% of the companies in the same industry.
Industry RankSector Rank
P/FCF 24.43
EV/EBITDA N/A
TXG Per share dataTXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

TXG's earnings are expected to grow with 15.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.87%
EPS Next 3Y15.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TXG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

10X GENOMICS INC-CLASS A

NASDAQ:TXG (12/15/2025, 8:00:02 PM)

After market: 15.76 0 (0%)

15.76

+0.3 (+1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)01-12 2026-01-12/amc
Inst Owners107.84%
Inst Owner Change-1.54%
Ins Owners1.6%
Ins Owner Change-2.51%
Market Cap1.99B
Revenue(TTM)641.81M
Net Income(TTM)-76.32M
Analysts73.04
Price Target16.86 (6.98%)
Short Float %13.56%
Short Ratio5.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)99.5%
Min EPS beat(2)24.4%
Max EPS beat(2)174.61%
EPS beat(4)3
Avg EPS beat(4)47.23%
Min EPS beat(4)-34.43%
Max EPS beat(4)174.61%
EPS beat(8)6
Avg EPS beat(8)27.95%
EPS beat(12)7
Avg EPS beat(12)13.27%
EPS beat(16)8
Avg EPS beat(16)1.94%
Revenue beat(2)2
Avg Revenue beat(2)13.16%
Min Revenue beat(2)3.54%
Max Revenue beat(2)22.78%
Revenue beat(4)4
Avg Revenue beat(4)11.15%
Min Revenue beat(4)2.51%
Max Revenue beat(4)22.78%
Revenue beat(8)5
Avg Revenue beat(8)4.76%
Revenue beat(12)9
Avg Revenue beat(12)4.17%
Revenue beat(16)11
Avg Revenue beat(16)2.67%
PT rev (1m)11.82%
PT rev (3m)10.22%
EPS NQ rev (1m)8.65%
EPS NQ rev (3m)11.32%
EPS NY rev (1m)18.96%
EPS NY rev (3m)26.97%
Revenue NQ rev (1m)1.19%
Revenue NQ rev (3m)3.43%
Revenue NY rev (1m)2.38%
Revenue NY rev (3m)2.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.11
P/FCF 24.43
P/OCF 22.53
P/B 2.54
P/tB 2.79
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)0.65
FCFY4.09%
OCF(TTM)0.7
OCFY4.44%
SpS5.07
BVpS6.2
TBVpS5.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.43%
ROE -9.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.9%
FCFM 12.72%
ROA(3y)-20.81%
ROA(5y)-25.31%
ROE(3y)-26.91%
ROE(5y)-32.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.17%
GM growth 5Y-2.02%
F-Score5
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 23.81%
Cap/Sales 1.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.48
Quick Ratio 4.06
Altman-Z 3.6
F-Score5
WACC10.46%
ROIC/WACCN/A
Cap/Depr(3y)231.92%
Cap/Depr(5y)289.86%
Cap/Sales(3y)11.9%
Cap/Sales(5y)13.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
EPS Next Y67.35%
EPS Next 2Y16.87%
EPS Next 3Y15.55%
EPS Next 5Y16.65%
Revenue 1Y (TTM)1.92%
Revenue growth 3Y7.58%
Revenue growth 5Y19.96%
Sales Q2Q%-1.75%
Revenue Next Year4.41%
Revenue Next 2Y0.38%
Revenue Next 3Y2.98%
Revenue Next 5Y4.05%
EBIT growth 1Y21.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.65%
EBIT Next 3Y16.93%
EBIT Next 5Y15.76%
FCF growth 1Y172.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y424.98%
OCF growth 3YN/A
OCF growth 5Y-28.08%

10X GENOMICS INC-CLASS A / TXG FAQ

Can you provide the ChartMill fundamental rating for 10X GENOMICS INC-CLASS A?

ChartMill assigns a fundamental rating of 4 / 10 to TXG.


What is the valuation status for TXG stock?

ChartMill assigns a valuation rating of 2 / 10 to 10X GENOMICS INC-CLASS A (TXG). This can be considered as Overvalued.


Can you provide the profitability details for 10X GENOMICS INC-CLASS A?

10X GENOMICS INC-CLASS A (TXG) has a profitability rating of 2 / 10.